Guidance Offered for Managing Pain in Patients With Cancer and OUD
For patients with opioid use disorder taking buprenorphine-naloxone, it is deemed appropriate to continue three times-daily dosing
For patients with opioid use disorder taking buprenorphine-naloxone, it is deemed appropriate to continue three times-daily dosing
54.7 percent used only nonopioid pain management strategies and 4.4 percent used opioids only
This study sought to identify predictors of severe pain during wound dressing change.
The current opioid crisis in the United States requires new approaches to prescription opioid management.
Cryotherapy applied over closed surgical incisions decreased postoperative pain and opioid consumption.
In a case-control study, researchers assessed risk factors for persistent neuropathic pain in those who have recovered from COVID-19 and observed their serum level of neurofilament light chain.
High-dose spinal cord stimulation was efficacious for the treatment of painful diabetic neuropathy.
Study data published in Neuropsychiatric Disease and Treatment outline the primary factors affecting attrition in buprenorphine treatment for opioid use disorder.
A decrease in the number of excess postoperative opioid medications resulted from the implementation of a mandatory prescription drug monitoring program.
The goal of the study was to assess whether certain aspects of pain intensity other than ‘average’ pain could be perceived as useful to healthcare providers.